June 2013, Vol 4 No 4 Novel Approaches in the Treatment of Hematologic Malignancies Utilizing Bendamustine

Novel Approaches in the Treatment of Hematologic Malignancies Utilizing Bendamustine

This is the fourth article in a 4-part series on bendamustine. While the previous articles discussed the efficacy and safety of bendamustine for patients with chronic lymphocytic leukemia (CLL) and non-Hodgkin lym­phoma (NHL) in the registration studies cited in the US product labeling, this article discusses ongoing clinical investigations of [ Read More ]


Advances in Bendamustine Clinical Trials

Bendamustine is currently approved for the treatment of chronic lymphocytic leukemia (CLL), and many ongoing studies are investigating its efficacy in drug combinations. Data in the relapsed/refractory setting are promising regarding improved overall survival and manageable toxicities, such as reversible myelosuppression, nausea, and fatigue – nursing implications mandate careful patient [ Read More ]

Colleen Ross, RN, MSN, MHA, OCN


The Developing Treatment Role of Bendamustine

Bendamustine has demonstrated activity as monotherapy and in combination for patients with lymphoid and hematologic as well as solid tumors. In the United States, bendamustine has been approved by the FDA for the treatment of patients with indolent B-cell non-Hodgkin lymphoma (NHL) who have progressed during or within 6 months [ Read More ]

Susanne Liewer, PharmD, BCOP


Bendamustine: Progress in Clinical Investigations

At the 54th Annual Meeting of the American Society of Hematology, a number of abstracts were presented demonstrating the efficacy and toxicities of bendamustine either alone or in combination with other agents for the treatment of several lymphoid malignancies such as chronic lymphocytic leukemia (CLL) and indolent as well as [ Read More ]

Julie M. Vose, MD, MBA